Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

WARRINGTON, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit.

The Company’s presentation will take place on Wednesday, September 22, 2021 at 9:55 am ET. A live webcast and replay of the presentation will be available on the Investor Events page (https://ir.windtreetx.com/events) of the company’s website (www.windtreetx.com).

About Windtree TherapeuticsWindtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and acute pulmonary disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. In pulmonary care, Windtree has focused on developing AEROSURF®, a drug-device combination, to deliver its synthetic KL4 surfactant non-invasively to premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee's HK. Windtree is also evaluating KL4 surfactant for the treatment of acute respiratory distress syndrome in COVID-19 patients. Also in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

For more information, please visit the Company's website at www.windtreetx.com.

Contact Information:Monique KosseLifeSci Advisors212.915.3820 or [email protected]

Media contact:Andrew MielachLifeSci Communications646.876.5868 or [email protected]

You May Also Be Interested In

• Purpose Investments Inc. Announces Updated April 2024 Distribution Rate and Record and Ex-Distribution dates for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund,
• Atlantic Canada’s airport security screeners take job action over GardaWorld’s non-payment of wages
• Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development